Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1

被引：4

作者：

Rossi, John M. ^{[1
]}

Galon, Jerome ^{[2
]}

Turcan, Sarah ^{[3
]}

Danan, Corinne ^{[3
]}

Locke, Frederick L. ^{[4
]}

Neelapu, Sattva S. ^{[5
]}

Miklos, David B. ^{[6
]}

Jacobson, Caron A. ^{[7
]}

Lekakis, Lazaros J. ^{[8
]}

Lin, Yi ^{[9
]}

Ghobadi, Armin ^{[10
]}

Go, William Y. ^{[1
]}

Bot, Adrian ^{[1
]}

机构：

[1] Kite, Santa Monica, CA USA

[2] UPMC Univ Paris, Sorbonne Univ, Univ Paris Descartes, INSERM, Paris, France

[3] HalioDx, Marseille, France

[4] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat, Tampa, FL USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Stanford Univ, Sch Med, Blood & Marrow Transplantat, Stanford, CA 94305 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Miami Hlth Syst, Sylvester Comprehens Canc Ctr, Miami, FL USA

[9] Mayo Clin, Div Hematol, Rochester, MN USA

[10] Washington Univ, Sch Med, Div Med Oncol, St Louis, MO USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-LB-016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LB-016

引用

页数：2

共 50 条

[1] Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)
Rossi, John M.
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Go, William Y.
Bot, Adrian
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S281 - S281
[2] Retreatment of Patients With Refractory Large B Cell Lymphoma With Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick
Bartlett, Nancy
Jacobson, Caron
Oluwole, Olalekan
Munoz, Javier
Lekakis, Lazaros
Topp, Max
Avivi, Irit
Kim, Jenny
Chu, Rong
Zheng, Lianqing
Rossi, John
Bot, Adrian
Neelapu, Sattva
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S21 - S22
[3] Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, Frederick L.
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S265 - S265
[4] Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1
Rossi, John M.
Galon, Jerome
Chang, Edmund
Perbost, Regis
Scholler, Nathalie
Turcan, Sarah
Danan, Corinne
Locke, Frederick L.
Neelapu, Sattva S.
Miklos, David B.
Jacobson, Caron A.
Lekakis, Lazaros J.
Lin, Yi
Ghobadi, Armin
Milletti, Francesca
Go, William Y.
Bot, Adrian
CANCER RESEARCH, 2019, 79 (13)
[5] Durability of response in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
Locke, Frederick Lundry
Ghobadi, Armin
Jacobson, Caron A.
Jacobsen, Eric D.
Miklos, David Bernard
Lekakis, Lazaros J.
Braunschweig, Ira
Oluwole, Olalekan O.
Lin, Yi
Siddiqi, Tanya
Deol, Abhinav
Reagan, Patrick Michael
Farooq, Umar
Bot, Adrian
Jiang, Yizhou
Rossi, John M.
Xue, Allen
Go, William Y.
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Axicabtagene Ciloleucel (Axi-Cel) In Patients With Refractory Large B Cell Lymphoma: Long-Term Safety and Efficacy of ZUMA-1
Neelapu, S. S.
Ghobadi, A.
Jacobson, C. A.
Miklos, D. B.
Lekakis, L. J.
Oluwole, O. O.
Lin, Y.
Braunschweig, I.
Hill, B. T.
Timmerman, J. M.
Deol, A.
Reagan, P. M.
Stiff, P.
Flinn, I. W.
Farooq, U.
Goy, A.
McSweeney, P. A.
Munoz, J.
Siddiqi, T.
Chavez, J. C.
Herrera, A. F.
Xue, A.
Jiang, Y.
Bot, A.
Rossi, J. M.
Kim, J. J.
Go, W. Y.
Locke, F. L.
BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 26 - 27
[7] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, F. L.
Bartlett, N. L.
Jacobson, C. A.
Oluwole, O. O.
Munoz, J.
Lekakis, L. J.
Topp, M. S.
Avivi, I
Kim, J. J.
Chu, R.
Zheng, L.
Rossi, J. M.
Bot, A.
Neelapu, S. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
[8] Outcomes of Patients Aged 65 Years in ZUMA-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Neelapu, Sattva S.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Deol, Abhinav
Miklos, David B.
Bartlett, Nancy L.
Braunschweig, Ira
Jiang, Yizhou
Kim, Jenny J.
Zheng, Lianging
Rossi, John M.
Locke, Frederick L.
AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S19 - S20
[9] DURABILITY OF ANSWERS IN THE ZUMA-1, PIVOTAL STUDY PHASE 2 OF AXICABTAGEN CILOLEUCEL (AXI-CEL) IN PATIENTS WITH LARGE CELL LYMPHOMA B REFRACTORY
Locke, F. L.
Ghobadi, A.
Jacobson, C. A.
Jacobsen, E.
Miklos, D. B.
Lekakis, L. J.
Braunschweig, I
Oluwole, O. O.
Lin, Y.
Siddiqi, T.
Deol, A.
Reagan, P. M.
Farooq, U.
Bot, A.
Jiang, Y.
Rossi, J. M.
Xue, A.
Go, W. Y.
Neelapu, Sattva S.
HAEMATOLOGICA, 2018, 103 : 95 - 96
[10] Axicabtagene Ciloleucel (Axi-cel) in Patients With Refractory Large B Cell Lymphoma (NHL): Long-term Follow-up of ZUMA-1
Locke, F. L.
Bartlett, N. L.
Lekakis, L. J.
Miklos, D. B.
Jacobson, C. A.
Braunschweig, I.
Oluwole, O. O.
Siddiqi, T.
Lin, Y.
Timmerman, J.
Reagan, P. M.
Bot, A.
Rossi, J. M.
Navale, L.
Jiang, Y.
Aycock, J. S.
Elias, M.
Wiezorek, J. S.
Go, W.
Neelapu, S. S.
BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 25 - 25

← 1 2 3 4 5 →